^
Association details:
| Biomarker: | KDM1A overexpression |
|---|---|
| Cancer: | Osteosarcoma |
| Drug: | seclidemstat (SP2577) (LSD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)
Published date:
08/28/2021
Excerpt:
SP-2577(Seclidemstat), an inhibitor of lysine-specific demthylase KDM1A (LSD1) that is overexpressed in pediatric sarcomas, was evaluated against pediatric sarcoma xenografts. SP-2577 (100 mg/kg/day × 28 days) statistically significantly (p < .05) inhibited growth of three of eight Ewing sarcoma (EwS), four of five rhabdomyosarcoma (RMS), and four of six osteosarcoma (OS) xenografts.
DOI:
10.1002/pbc.29304
